148 related articles for article (PubMed ID: 1883984)
1. Mechanism of action of isosorbide-5-mononitrate in reducing portal pressure in cirrhotic patients with cirrhosis and portal hypertension.
Jenkins SA; Shields R
J Gastroenterol Hepatol; 1991; 6(1):91-3. PubMed ID: 1883984
[No Abstract] [Full Text] [Related]
2. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
3. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension.
Piscaglia F; Donati G; Gaiani S; Gramantieri L; Leoni S; Mancini M; Bolondi L
Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844
[TBL] [Abstract][Full Text] [Related]
4. Effect and mechanism of action of isosorbide-5-mononitrate.
Hayes PC; Westaby D; Williams R
Gut; 1988 Jun; 29(6):752-5. PubMed ID: 3384359
[TBL] [Abstract][Full Text] [Related]
5. Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver.
Cervinka J; Kordac V; Kalab M
J Int Med Res; 1989; 17(6):560-4. PubMed ID: 2628133
[TBL] [Abstract][Full Text] [Related]
6. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
[TBL] [Abstract][Full Text] [Related]
7. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.
Villanueva C; López-Balaguer JM; Aracil C; Kolle L; González B; Miñana J; Soriano G; Guarner C; Balanzó J
J Hepatol; 2004 May; 40(5):757-65. PubMed ID: 15094222
[TBL] [Abstract][Full Text] [Related]
9. Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients.
Bolognesi M; Sacerdoti D; Merkel C; Gatta A
J Ultrasound Med; 1994 Dec; 13(12):945-52. PubMed ID: 7877205
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
Garcia-Pagán JC; Navasa M; Bosch J; Bru C; Pizcueta P; Rodés J
Hepatology; 1990 Feb; 11(2):230-8. PubMed ID: 2307401
[TBL] [Abstract][Full Text] [Related]
11. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
García-Pagán JC; Feu F; Bosch J; Rodés J
Ann Intern Med; 1991 May; 114(10):869-73. PubMed ID: 2014947
[TBL] [Abstract][Full Text] [Related]
12. The effect of a combined treatment with propranolol and isosorbide-5-mononitrate on Doppler ultrasound parameters in patients with cirrhosis and portal hypertension.
Orban Schiopu AM; Balas BI; Diculescu M
Rom J Gastroenterol; 2005 Jun; 14(2):123-7. PubMed ID: 15990930
[TBL] [Abstract][Full Text] [Related]
13. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.
Navasa M; Chesta J; Bosch J; Rodés J
Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055
[TBL] [Abstract][Full Text] [Related]
14. Duplex Doppler ultrasonographic comparison of the effects of propranolol and isosorbide-5-mononitrate on portal hemodynamics.
Tincani E; Cioni G; Cristani A; D'Alimonte P; Vignoli A; Abbati G; Ventura P; Romagnoli R; Ventura E
J Ultrasound Med; 1993 Sep; 12(9):525-9. PubMed ID: 8107184
[TBL] [Abstract][Full Text] [Related]
15. Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.
Hallemans R; Naeije R; Mols P; Mélot C; Reding P
Crit Care Med; 1983 Jul; 11(7):536-40. PubMed ID: 6861502
[TBL] [Abstract][Full Text] [Related]
16. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.
Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC
J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395
[TBL] [Abstract][Full Text] [Related]
17. Effect of sublingual isosorbide dinitrate on wedged hepatic venous pressure in cirrhotics with portal hypertension.
Qureshi H; Zuberi SJ; Faruqui A
Indian J Gastroenterol; 1988 Jul; 7(3):161-2. PubMed ID: 3397139
[No Abstract] [Full Text] [Related]
18. Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.
Freeman JG; Barton JR; Record CO
Br Med J (Clin Res Ed); 1985 Aug; 291(6495):561-2. PubMed ID: 3929873
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.
Merkel C; Sacerdoti D; Bolognesi M; Enzo E; Marin R; Bombonato G; Angeli P; Gatta A
Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449
[TBL] [Abstract][Full Text] [Related]
20. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.
García-Pagán JC; Feu F; Navasa M; Bru C; Ruiz del Arbol L; Bosch J; Rodés J
J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
